Targinact | 92522-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: Targinact
• 英文别名: (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;(4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
• CAS: 92522-88-8
• 化学式: C37H42N2O8
• 分子量: 642.7
• InChiKey: ACSGYQDUMAPFHC-ONHRPZMOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.35
• 重原子数：
  47
• 可旋转键数：
  3
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  129
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Dosage form containing oxycodone and naloxone
  申请人：Euro-Celtique S.A.

  公开号：EP1695700A1

  公开（公告）日：2006-08-30

  The present invention concerns a dosage form comprising oxycodone and naloxone which characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.

  本发明涉及一种由羟考酮和纳洛酮组成的剂型，其特征在于特定的体内参数，如 tmax、Cmax、AUCt 值、平均肠功能评分和/或镇痛疗效持续时间。
• Method and device for the assessment of bowel function
  申请人：Euro-Celtique S.A.

  公开号：EP1702558A1

  公开（公告）日：2006-09-20

  The present invention provides a method for assessing bowel function in a patient, comprising providing the patient with a numeric analog scale for at least one parameter which is a measure of bowel function; causing the patient to indicate on the numeric analog scale the amount and/or intensity of the parameter being experienced; and observing the amount and/or intensity of the at least one parameter indicated on the numeric analog scale in order to assess bowel function. Further, the present invention provides a device for assessing bowel function in a patient, the device comprising a display unit for providing a numeric analog scale for at least one parameter which is associated with bowel function of a patient; a receiving unit adapted to receive an amount and/or intensity of the at least one parameter indicated by the patient on the numeric analog scale; and an interface unit adapted to provide the amount and/or intensity of the at least one parameter indicated on the numeric analog scale in order to assess bowel function.

  本发明提供了一种评估患者肠道功能的方法，包括为患者提供至少一个衡量肠道功能的参数的数字模拟量表；使患者在数字模拟量表上显示正在经历的参数的量和/或强度；以及观察数字模拟量表上显示的至少一个参数的量和/或强度，以评估肠道功能。 此外，本发明还提供了一种用于评估患者肠道功能的设备，该设备包括一个显示单元，用于提供与患者肠道功能相关的至少一个参数的数字模拟量表；一个接收单元，适于接收患者在数字模拟量表上指示的至少一个参数的量和/或强度；以及一个接口单元，适于提供数字模拟量表上指示的至少一个参数的量和/或强度，以便评估肠道功能。
• Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
  申请人：EURO-CELTIQUE S.A.

  公开号：EP2042176A1

  公开（公告）日：2009-04-01

  The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.

  本发明涉及使用阿片类激动剂和拮抗剂的组合来治疗克罗恩病。
• Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease and the symptoms associated with Crohn's disease
  申请人：EURO-CELTIQUE S.A.

  公开号：EP2042177A1

  公开（公告）日：2009-04-01

  The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.

  本发明涉及使用阿片类激动剂和拮抗剂的组合来治疗克罗恩病。
• DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE
  申请人：EURO-CELTIQUE S.A.

  公开号：EP1855657A2

  公开（公告）日：2007-11-21